All posts

Follow Us

LinkedInInstagramX
Quarterly ResultsArchiveLast updated 19 November 20262 min read

Vaxfab (VEL) Q2 FY27 Profit Swings Positive as Revenue Falls 50%

Vaxfab Enterprises posted a small profit in Q2 FY27, but a steep revenue drop and a qualified audit point to deeper instability.

By Anant Kacholia, HexaWealth Research · Created 19 November 2026

Vaxfab Enterprises reported a Q2 FY27 profit of ₹1.37 crore, a sharp swing from the prior quarter's loss. However, revenue fell over 50% year-on-year, and auditors flagged over ₹100 crore in unverifiable balances.

For a trading business, consistency is the only real asset. Vaxfab Enterprises' September quarter delivered a nominal profit after a disastrous June, but the underlying story is one of extreme volatility and unresolved governance questions that overshadow the bottom-line improvement.

The standalone numbers show a profit of ₹1.37 crore on revenue of ₹27.19 crore. Yet revenue is still down more than half from the same quarter last year. The profit swing is largely technical, emerging from a loss in the prior quarter where revenue was nearly zero.

Revenue & profit

Revenue (₹ Cr)

Profit (₹ Cr)

Revenue & profitSep 2025 (Q2 FY26) 55.04, Dec 2025 (Q3 FY26) 15.66, Mar 2026 (Q4 FY26) 45.99, Jun 2026 (Q1 FY27) 0.40, Sep 2026 (Q2 FY27) 27.19. Sep 2025 (Q2 FY26) -2.28, Dec 2025 (Q3 FY26) -3.23, Mar 2026 (Q4 FY26) 2.14, Jun 2026 (Q1 FY27) -3.04, Sep 2026 (Q2 FY27) 1.37-80-4004080Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
  • Revenue (₹ Cr), Sep 2025 (Q2 FY26): 55.04
  • Revenue (₹ Cr), Dec 2025 (Q3 FY26): 15.66
  • Revenue (₹ Cr), Mar 2026 (Q4 FY26): 45.99
  • Revenue (₹ Cr), Jun 2026 (Q1 FY27): 0.40
  • Revenue (₹ Cr), Sep 2026 (Q2 FY27): 27.19
  • Profit (₹ Cr), Sep 2025 (Q2 FY26): -2.28
  • Profit (₹ Cr), Dec 2025 (Q3 FY26): -3.23
  • Profit (₹ Cr), Mar 2026 (Q4 FY26): 2.14
  • Profit (₹ Cr), Jun 2026 (Q1 FY27): -3.04
  • Profit (₹ Cr), Sep 2026 (Q2 FY27): 1.37

Revenue (₹ Cr)

Revenue (₹ Cr)Sep 2025 (Q2 FY26) 55.04, Dec 2025 (Q3 FY26) 15.66, Mar 2026 (Q4 FY26) 45.99, Jun 2026 (Q1 FY27) 0.40, Sep 2026 (Q2 FY27) 27.19020406080Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
  • Revenue (₹ Cr), Sep 2025 (Q2 FY26): 55.04
  • Revenue (₹ Cr), Dec 2025 (Q3 FY26): 15.66
  • Revenue (₹ Cr), Mar 2026 (Q4 FY26): 45.99
  • Revenue (₹ Cr), Jun 2026 (Q1 FY27): 0.40
  • Revenue (₹ Cr), Sep 2026 (Q2 FY27): 27.19

Profit (₹ Cr)

Profit (₹ Cr)Sep 2025 (Q2 FY26) -2.28, Dec 2025 (Q3 FY26) -3.23, Mar 2026 (Q4 FY26) 2.14, Jun 2026 (Q1 FY27) -3.04, Sep 2026 (Q2 FY27) 1.37-4-2024Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
  • Profit (₹ Cr), Sep 2025 (Q2 FY26): -2.28
  • Profit (₹ Cr), Dec 2025 (Q3 FY26): -3.23
  • Profit (₹ Cr), Mar 2026 (Q4 FY26): 2.14
  • Profit (₹ Cr), Jun 2026 (Q1 FY27): -3.04
  • Profit (₹ Cr), Sep 2026 (Q2 FY27): 1.37

Net Profit Margin

Net Profit MarginSep 2025 (Q2 FY26) -4.1%, Dec 2025 (Q3 FY26) -20.7%, Mar 2026 (Q4 FY26) 4.7%, Jun 2026 (Q1 FY27) —, Sep 2026 (Q2 FY27) 5.0%-40%-20%0%20%40%Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
  • Net Profit Margin, Sep 2025 (Q2 FY26): -4.1%
  • Net Profit Margin, Dec 2025 (Q3 FY26): -20.7%
  • Net Profit Margin, Mar 2026 (Q4 FY26): 4.7%
  • Net Profit Margin, Jun 2026 (Q1 FY27): —
  • Net Profit Margin, Sep 2026 (Q2 FY27): 5.0%
MetricCurrentSep 2026 (Q2 FY27)PreviousJun 2026 (Q1 FY27)
Revenue (₹ Cr)
27.19
0.40
Profit (₹ Cr)
1.37
-3.04
Net Profit Margin
5.0%
—

The profit's fragile foundation

A MarketsMojo analysis notes the core trading margin remains anaemic at 2.37%. Nearly 40% of the quarter's operating profit came from other income, not core operations. This reliance on non-trading income makes the reported profit look more sustainable than it is.

The company's financial controls are under a cloud. The statutory auditor issued a qualified review, stating it could not verify the completeness of trade receivables and payables exceeding ₹100 crore due to missing records from the previous management.

Borrowings rise to fund a broken cycle

Working capital is severely strained. According to MCapital, consolidated borrowings jumped by over ₹18 crore in just six months to ₹62.58 crore. This debt is funding receivables that the auditor cannot fully verify, creating a risky cash cycle.

Live Chart

· VEL

(BSE)

ISIN: INE560T01015

The market's reaction was mutedly negative. The stock closed 0.7% lower on the results day, as reported by MarketPing, suggesting investors saw through the headline profit to the structural concerns.

Key Points

  • A nominal Q2 profit of ₹1.37 crore follows a quarter of near-zero revenue, but yearly sales fell 50.6%.
  • The auditor qualified its review over ₹100+ crore in unverifiable receivables and payables, citing missing prior-period records.
  • Consolidated borrowings surged to ₹62.58 crore to fund working capital, amplifying balance sheet risk.
  • The stock fell 0.7% on the results day, reflecting market skepticism about the sustainability of the turnaround.

Hexa Perspective

The quarter presents a contradiction: a profit on paper amidst operational disarray. The qualified audit opinion is a severe red flag, casting doubt on the reliability of all reported assets and liabilities. The business model appears unable to generate stable revenue or adequate margins from its core trade. Until the forensic audit into past years is complete and the working capital cycle is repaired with verified collections, the company's financial statements offer a shaky foundation for any investment thesis. The path forward depends less on quarterly sales and more on restoring basic financial governance.

Share or follow HexaWealth

Also read

Want this applied to your portfolio?

Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.

Vaxfab Enterprises (VEL) Q2 FY27 results, revenue and profits.

Frequently asked questions

What were Vaxfab Enterprises' Q2 FY27 results?
Vaxfab Enterprises reported standalone Q2 FY27 revenue of ₹27.19 crore and a net profit of ₹1.37 crore for the quarter ended September 2026. On a consolidated basis, revenue was ₹51.04 crore with a profit of ₹1.13 crore. However, the half-year period remained loss-making.
Why did Vaxfab Enterprises' Q2 FY27 revenue fall over 50% year-on-year?
Vaxfab's Q2 FY27 standalone revenue of ₹27.19 crore fell 50.6% from ₹55.04 crore in Q2 FY26. The decline points to severe inconsistency in its trading operations, with quarterly revenue fluctuating wildly from zero to over ₹50 crore in recent periods.
What drove the year-on-year improvement in Vaxfab's net profit margin?
Vaxfab's net profit margin improved to 5.0% in Q2 FY27 from -4.1% a year ago, a 910 basis point gain. This shift is primarily because the year-ago quarter posted a loss. The current margin remains thin and, as MarketsMojo notes, relied significantly on other income.
Was Vaxfab Enterprises' Q2 FY27 profit driven by core operations?
No, a significant portion was not. Analysis by MarketsMojo indicates that nearly 40% of the quarter's operating profit came from other income. The core trading business generated an operating margin of just 2.37%, highlighting weak profitability from its main activities.
Why did total expenses increase 376% quarter-on-quarter?
Total expenses rose sharply in Q2 FY27 because the previous quarter (Q1 FY27) had virtually no revenue (₹0.4 crore) and thus minimal operating costs. The expense increase in Q2 simply corresponded with the return of trading activity, not necessarily runaway cost inflation.
What guidance did Vaxfab management provide for future quarters?
No specific management guidance from a concall is noted in the research. However, external analysis from MCapital projects full-year revenue may decline 20-27% from FY26 levels, with the company likely to remain loss-making over the next twelve months.
What is the state of Vaxfab's working capital and cash flow?
Working capital is severely stressed. MCapital estimates receivables imply a cycle of about 490 days, far above the reported 16 days. Consolidated borrowings rose ₹18.35 crore in six months to ₹62.58 crore to fund this stretched cycle, while cash remains low at ₹2.58 crore.
What are the key risks for Vaxfab Enterprises?
The primary risks are governance and financial controls. The auditor could not verify over ₹100 crore in receivables and payables due to missing records. A forensic audit is underway for past years, and the company faces GST notices on historical transactions, creating potential liability overhangs.
How did Vaxfab's stock price react to the Q2 results?
The stock reacted negatively. According to MarketPing, it closed 0.7% lower on the reaction day following the November 14 announcement, underperforming its industry median slightly. This suggests the market was unconvinced by the quarterly profit.
Are institutional investors increasing their stake in Vaxfab?
No, institutional ownership is virtually non-existent. MarketsMojo data shows FII holding is a mere 0.04%, with zero promoter and mutual fund stakes. This absence signals a lack of confidence from sophisticated investors in the company's prospects.
Vaxfab Enterprises Q2 FY27 results order book
The research snippets reviewed do not provide any information about an order book or backlog for Vaxfab Enterprises' textile trading business in Q2 FY27. The company's performance appears driven by sporadic trading transactions rather than a visible pipeline.
Vaxfab Enterprises forensic audit
On November 3, 2026, Vaxfab's board appointed ASGM & Co. to conduct an independent forensic accounting investigation for FY2022-23 to FY2024-25. This was prompted by missing records after a management change in April 2025 and received GST notices on historical transactions.